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There is growing interest in using embryonic stem
cell (ESC) and induced pluripotent stem cell
(iPSC) derivatives for tissue regeneration. However,
an increased understanding of human immune re-
sponses to stem cell-derived allografts is necessary
for maintaining long-term graft persistence. To
model this alloimmunity, humanized mice engrafted
with human hematopoietic and immune cells could
prove to be useful. In this study, an in-depth analysis
of graft-infiltrating human lymphocytes and spleno-
cytes revealed that humanized mice incompletely
model human immune responses toward allogeneic
stem cells and their derivatives. Furthermore, using
an ‘‘allogenized’’ mouse model, we show the feasi-
bility of reconstituting immunodeficient mice with a
functional mouse immune system and describe a
key role of innate immune cells in the rejection of
mouse stem cell allografts.INTRODUCTION
Since the first isolation of human embryonic stem cells (hESCs)
(Thomson et al., 1998) and creation of induced pluripotent
stem cells (iPSCs) (Takahashi et al., 2007; Takahashi and Yama-
naka, 2006), the field of regenerative medicine has been investi-
gating the therapeutic potential of these cells for cardiac
diseases (Nguyen et al., 2016), neurological diseases (Barberi
et al., 2003), hepatic failure (Soto-Gutiérrez et al., 2006), diabetes
(Pagliuca et al., 2014), and macular degeneration (Homma et al.,
2013). Human clinical trials in immune-privileged areas, such
as the eye for macular degeneration, are ongoing for ESC deriv-
atives (Schwartz et al., 2012) or iPSC derivatives (Mandai et al.,1978 Cell Reports 20, 1978–1990, August 22, 2017 ª 2017 The Autho
This is an open access article under the CC BY license (http://creative2017). However, the immunological responses toward these
derivatives in less immune-privileged sites are still poorly under-
stood (de Almeida et al., 2013). Recently, advances have
been made in tolerizing mice to accept human ESC- and iPSC-
derived progenitor grafts for long-term monitoring of graft
behavior (Lui et al., 2014). However, to date, it is still not clear
how the human immune system would respond to allogeneic
human ESC or iPSC grafts. This question would need to be
answered before pluripotent stem cell (PSC) therapy, including
both ESCs and iPSCs, could be widely implemented in clinical
practice.
To model human immune responses, researchers have been
studying immunodeficient mice engrafted with human immune
cells and their progenitors, such as peripheral blood mononu-
clear cells (PBMCs) and hematopoietic stem cells (HSCs). The
first description of these ‘‘humanized mouse models’’ dates
back to 1983, when it was reported that the Prkdcscid (severe
combined immunodeficiency, scid) mutation in CB17 mice
caused B and T cell deficiency (Bosma et al., 1983) and
suggested that CB17-scid mice would be permissive for human
HSC and PBMC engraftment. However, because of the high
levels of host natural killer (NK) cell activity and the spontaneous
generation ofmouse B and T cells, thismodel supported only low
levels of human HSC engraftment (Greiner et al., 1998). With the
expression of human-like SIRPA in the non-obese diabetic
(NOD)-scid strain, the levels of murine NK cells decreased
(Shultz et al., 1995; Takenaka et al., 2007), resulting in height-
ened engraftment of human PBMCs (Hesselton et al., 1995).
However, residual activity of NK cells as well as other innate
immune system functions interfered with human HSC engraft-
ment.Moreover, NOD-scidmice developed spontaneous thymic
lymphomas, resulting in a shortened lifespan. It was not until the
NOD-scid mouse strain with the interleukin-2 receptor gamma
chain (IL2rg)-targeted mutation (NOD.Cg-Prkdcscid IL2rgtm1Wj1/
Sz, NOD scid gamma [NSG]) and related NOD/shi-scid/gc null
(NOG) strain mice were repopulated with human HSCsr(s).
commons.org/licenses/by/4.0/).
(scid-repopulating cell, hSRC mouse), that superior human
hematopoietic and immune cell engraftment was achieved (Ishi-
kawa et al., 2005; Ito et al., 2002; Shultz et al., 2005).
Despite enhanced engraftment of human HSCs in immunode-
ficient IL2rgnull mice, a robust human T cell-mediated immune
response could not be established (Traggiai et al., 2004). The
relatively weak T cell response was hypothesized to be due to
the lack of human leukocyte antigen (HLA) on the murine thymus
that is necessary for the positive selection of human T cells. To
address this, a new model was created by subcapsular renal
implantation of human liver and thymus fragments as well as
intravenous injection of autologous (human liver-derived) HSCs
in sublethally irradiated immunodeficient mice and was termed
the human bone marrow, liver, and thymus (hBLT) model (Lan
et al., 2006; Melkus et al., 2006). The superior engraftment of
human immune cells combined with positive selection of
T cells in the autologous human thymus has made this the
preferred model for studying human immune responses to infec-
tion (Brehm et al., 2014).
An emerging field where humanized mice could prove to be
useful is the study of human immune responses to allogeneic
PSC transplants to assess the efficacy and safety of PSCs
and guide effective immunosuppressive therapies. Here we
describe the use of hSRC and hBLT humanized NSG mice to
model the human immune response to allogeneic hESCs and
their derivatives. We track allograft survival over time using
bioluminescence imaging (BLI). In addition, we provide large
transcriptome data as well as single-cell immunological analysis
of human graft-infiltrating T cells and splenocytes isolated from
humanized mice. Furthermore, using a similar implantation of
mouse liver, thymus, and bone marrow, we developed an ‘‘allo-
genized’’ mouse model as a surrogate to assess allogeneic
immunological responses to murine PSC allografts in vivo and
ex vivo.
RESULTS
Human Immune-Engrafted NSG Mice Are Unable to
Completely Reject Allogeneic hESCs
We used both the hSRC (NSG mice engrafted with HLA-A2neg
HSCs) and hBLT (NSG mice engrafted with HLA-A2neg HSCs
and fetal tissue) to model the allogeneic human immune
responses to HLA-mismatched (HLA-A2pos) hESCs. The hESCs
were stably transduced with a reporter construct containing the
ubiquitin promoter driving firefly luciferase (Luc) and EGFP. Allo-
geneic HLA-A2pos hESCs (13 105) were implanted either subcu-
taneously (s.c.) or intramuscularly (i.m.) into hSRC mice. The
hESC survival in these mice, as well as in control non-engrafted
NSG and immunocompetent C57BL/6 mice, was longitudinally
monitored in vivo using BLI. Both the hSRC and non-engrafted
NSG mice were unable to completely reject allogeneic hESCs
implanted at either injection site, whereas the immunocompetent
C57BL/6 mice completely rejected the hESC grafts within
2 weeks (Figures S1A, S1C, S1D, and S1F).
To investigate whether low expression of major histocompat-
ibility complex class I (MHC class I) in hESCs played a role in the
failure of hSRC mice to reject these cells, hESCs were treated
with interferon gamma (IFN-g) for 24 hr prior to implantationinto hSRC mice to increase expression of MHC class I and cell
immunogenicity (Drukker et al., 2002). MHC class I, encompass-
ing HLA A, B, and C in humans, encodes the main molecular
targets of allograft rejection as well as MHC-associated incom-
patibilities between donor and recipient. It is also responsible
for almost all acute rejection. Indeed, upregulation of MHC class
I, as well as multiple other co-stimulatory molecules, was seen in
hESCs upon stimulation with IFN-g (Figure S2). However, even
the IFN-g-stimulated hESCs were not rejected by hSRC mice
(Figures S1B, S1C, S1E, and S1F). To address the possibility
that the inability to reject these hESCs may be due to the hESCs
modulating the immune response locally and enforcing toler-
ance, we transplanted hSCR mice with murine ESCs (mESCs),
which should normally be rejected by human immune cells.
However, these humanized mice were unable to reject murine
cells as well (Figures S1G and S1H).
Having provided evidence for the inability of the hSRC model
to mount strong PSC-directed immune responses, we moved to
the hBLT model. hBLT mice support robust human cell engraft-
ment of mouse lymphoid tissues and development of functional
human T lymphocytes (Lan et al., 2006; Melkus et al., 2006).
Indeed, total human leukocyte engraftment in hBLT mice in pe-
ripheral blood 12 weeks after humanization showed superior
engraftment of B cells and CD4+ T cells compared with the
hSRC model (Figures S3A and S3B).
We next tested the ability of hBLT mice to reject human
and mouse PSCs. Similar to the hSRC model, hBLT mice were
transplanted with mouse iPSC (miPSC) grafts, generated from
fibroblasts of a transgenic FVB mouse ubiquitously expressing
EGFP and Luc (de Almeida et al., 2014; Figure 1A), or with human
IFN-g-stimulated hESC allografts (Figure 1B) by intra-splenic
(i.s.) injection. The survival of the grafts was again monitored
using BLI, with the signal normalized to the maximum radiance
on day 1 of transplantation (Figure 1C). Despite superior engraft-
ment of human immune cell subsets in hBLT mice compared
with hSRCmice, the murine and human grafts were not rejected
and underwent proliferative growth that resulted in large
teratoma formation by week 4 and week 3, respectively
(Figure S3C).
hBLT Mice Showed a Correlation between Pro-
inflammatory Graft Infiltration and Graft Loss but Were
Unable to Fully Reject Differentiated hESC-EC Grafts
Next, we derived mature endothelial cells from the labeled
hESC line (hESC-ECs) to upregulate MHC class I molecules
on ESCs, which has been described during differentiation of
hESCs (Drukker et al., 2002). Upregulation of MHC class I mol-
ecules as well as several other co-stimulatory molecules was
confirmed by differentiating hESCs using the embryoid body
method (Figure S2). hESC-ECs (1 3 105) were then either trans-
planted s.c. in the back or i.m. in the gastrocnemius muscle of
hBLT mice at 20 weeks after humanization, and graft survival
was measured over time using BLI (Figure 2A). An initial decline
in signal, representative of non-immune-mediated cell stress
and loss during injections, was followed by stabilization of the
signal and persistence of the graft for the duration of the study.
Within the grafts, there appeared to be minimal immune cell
infiltration (Figures S3D and S3E). The signal kinetics ofCell Reports 20, 1978–1990, August 22, 2017 1979
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Figure 1. hBLT Mice Fail to Completely Reject Mouse iPSC Grafts and Allogeneic Human ESC Grafts
(A and B) Representative BLI from one mouse per group, demonstrating the proliferation of miPSCs (A), and IFN-g-hESCs (B) after i.s. injection in NSG (n = 3) and
hBLT mice (n = 5) and rejection of these cells in the immunocompetent (C57BL/6) recipients (n = 4).
(C) Quantification of the BLI data normalized to themaximum radiance on day 1, showing intensification of the signal over time for transplantedmiPSCs as well as
IFN-g-hESCs in NSG and hBLTmice, respectively, resulting in teratoma formation (left and center). In contrast, complete immune rejection of miPSCs and IFN-
g-hESCs occurred in immunocompetent C57BL/6 mice by 21 and 14 days, respectively (right).
BLI data are represented as mean ± SEM of two independent experiments.hESC-ECs in hBLT mice were very similar or, in some cases,
even improved compared with those in non-engrafted NSG
mice, indicating that the reconstituted immune system might
even favor graft persistence. In contrast, the signal in immuno-
competent FVB mice returned to baseline within 2 weeks, indi-
cating complete rejection of the hESC-EC grafts (Figure 2B). To
be sure that the limited immune response was not the result of
possible immune-evasive properties of hESC-ECs, we per-
formed an additional experiment by transplanting labeled
somatic human umbilical vein endothelial cells (HUVECs) into
16-week-old hBLT mice. Similar to the hESC-EC experiment,
hBLT mice were unable to fully reject the HUVECs with graft
persistence over a course of 3 weeks, whereas immunocompe-
tent FVB mice rejected the cells within a week after transplan-
tation (Figure S4).
It is important to note that, over the course of the 4-week
experiments, the condition of the hBLT mice deteriorated, with
decreased body weight, fur loss, and lessened physical activity.
For three hBLT mice, this necessitated euthanization. Uncertain
about the cause of this increased morbidity and mortality, we
analyzed the blood, spleen, draining inguinal lymph nodes1980 Cell Reports 20, 1978–1990, August 22, 2017(dLNs), and PSC grafts for human immune cell populations in
the remaining 12 hBLT mice at 4 weeks (Table S1). Blood
analyses of total CD4+ helper T cells showed the presence of
64.5% ± 5.2% naive (CD45RA+) T cells, 11.9% ± 2.8% activated
memory helper T cells (CD45RO+), and 7.6% ± 3.6% effector
memory (CD44+) helper T cells (Figure 3A, left). For CD8+ cyto-
toxic T cells, the levels of naive cells decreased to 53.4% ±
6.4%, and they gained a more activated memory function with
CD45RO+ T cell levels at 20.6% ± 2.9% and cytotoxic effector
memory cells at 21.0% ± 6.3% (Figure 3A, right). Only a very
small percentage of human CD3+ cells (0.4% ± 0.1%) was found
in the dLNs, indicating that active human cells found in the sys-
temic circulation were unable to traffic or localize appropriately
to the dLNs (Figure 3B). In addition, the dLNs contained very
few human B cells or antigen-presenting cells. Analysis of the
spleens showed substantial engraftment of human B and T lym-
phocytes but few monocytes or NK cells (Figure 3C). The
subpopulations of CD3+ lymphocytes consisted mainly of helper
T cells and few cytotoxic T cells that were largely naive, with very
few effector memory cells observed. Within the grafts, the
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Figure 2. hBLT Mice Are Unable to Reject hESC-EC Grafts
(A) Representative BLI from one animal per group over the course of 4 weeks, showing persistence of hESC-ECs after s.c. and i.m. injection in NSG (center, n = 5)
and hBLT (right, n = 12) mice, whereas the immunocompetent FVB mice (left, n = 4) completely rejected the grafts by day 14.
(B) Quantification of the BLI data normalized to the maximum radiance on day 1, showing initial non-immune-mediated graft loss followed by graft persistence in
the subcutaneous (top) and gastrocnemius muscle (bottom) injection sites in NSG and hBLT mice and complete rejection by the FVB mice.small percentages of effector memory CD4+ (1.3% ± 0.3%) and
CD8+ (7.0% ± 1.3%) cells (Figure 3D). However, there was a
strong correlation between graft loss, as indicated by the rela-
tionship between the decay in BLI signal, a reduction in the num-
ber of regulatory FoxP3+ T cells and naive T cells (Figure 3E, left
and center), and an increase in the amount of activated immune
cells in the graft (Figure 3E, right). Again, the presence of inactive
and immunosuppressive immune cells in the graft environment
might favor graft persistence, whereas activated immune cells
facilitated graft loss.
Taken together, our data suggest that these mice had an acti-
vated systemic immune system in the blood, but these active
immune cells were not seen in similar quantities in the spleen,
dLNs, or graft. Nevertheless, the limited numbers of activated
graft-infiltrating T cells correlated strongly with graft loss. This
revealed some functionality of the immune system in hBLT
mice but also showed that they are incapable of mounting an
effective alloimmune response to completely reject hESC-ECs.In-depth Analyses of Immune Cells from hESC-EC-
Engrafted hBLT Mice Show a ‘‘Non-stimulated’’ T Cell
Phenotype
Immune cells isolated from spleens, dLNs, and Matrigel plugs
from hESC-EC-engrafted mice were used for mixed lymphocyte
reactions to assess the effectiveness of the different lymphoid
structures in mounting an immune response. First, immune cells
isolated from the blood and spleen of hBLTmicewere stimulated
with phorbol ester (phorbol myristate acetate [PMA])/ionomycin,
and their activation was compared with positive control samples
of HiCK-1 cells and PBMCs isolated from human whole blood
(Figure S5A). Even though some pro-inflammatory responses
were seen in the splenocytes of hBLT mice, this was reduced
compared with the positive control samples. Second, immune
cells isolated from the Matrigel plugs and dLNs were incubated
with hESC-EC lysate or HUVEC lysate to compare specific and
non-specific immune responses (Figure S5B). In this experiment,






Figure 3. hBLTMiceReveal Systemic ImmuneActivation, with a StrongCorrelation between Small Numbers of HumanGraft-InfiltratingCells
and Rejection of Allogeneic hESC-ECs
(A and B) FACS analysis of (A) blood shows an active (CD45RO+; CD44+) systemic cytotoxic T cell (CD8+) response but (B) little population of T cells as well as
B cells and macrophages in the inguinal dLNs.
(C) Analysis of the spleen reveals larger populations of B cells (CD20+) and T cells (CD3+), but subpopulations of the latter show relatively high numbers of naive
(CD45RA) and few effector memory (CD44+) T cells.
(D) Limited numbers of graft-infiltrating lymphocytes consist mainly of naive T cells with few effector memory cells.
(E) The decrease in BLI signal (Max Radiance) in the graft was significantly correlated with a lower number of regulatory T cells (FoxP3, left) and naive T helper cells
(CD45RA, center) and an increase in activated T helper cells (CD45RO, right).
Data are displayed as percentage (%) or number of cells (counts) within the parent population, e.g. in CD45/CD3/CD4/CD8 cells. Data are represented as
mean ± SEM from one experiment (n = 12).immune cell activation. Moreover, non-antigen stimulation by
PMA/ionomycin also did not result in T cell activation. We next
analyzed the gene expression profile of the small population of
activated graft-infiltrating lymphocytes. As negative and positive
controls for T cell activation, PBMCs from a healthy human donor
remained unstimulated or were stimulated in vitro with PMA/ion-
omycin for 72 hr. After 72 hr, the PBMCs were harvested and,
together with the hBLT lymphocytes, stained for murine and hu-
man CD45 markers and human CD3, CD4, CD8, CD45RA, and
CD45RO. Human lymphocytes with an activated memory sur-
face marker profile (CD4+CD45RO+; CD8+CD45RO+) were iso-
lated using fluorescence-activated cell sorting (FACS), and their1982 Cell Reports 20, 1978–1990, August 22, 2017gene expression was analyzed with the Fluidigm single-cell PCR
platform using a panel of 92 genes known to be involved with hu-
man Th1, Th2, and Th3 immune responses (Table S2).
Principal-component analysis (PCA) of the fold changes of all
92 genes revealed that hBLT CD3+ lymphocytes isolated from
the grafts grouped with the unstimulated control human T lym-
phocytes (Figure 4A). Activated human helper T cells
(CD4+CD45RO+) and cytotoxic T cells (CD8+CD45RO+) isolated
from hBLT spleens showed a similar grouping to their unstimu-
lated counterparts from the healthy control (Figures 4B and
4C). These activated memory graft-infiltrating lymphocytes and






Figure 4. Single-Cell PCRAnalysis and RNA-Seq of hBLTGraft-Infiltrating T Lymphocytes, dLNs, and Splenocytes Reveals the Unstimulated
Phenotype
(A)Graft-infiltrating lymphocyte (CD3+,blue)groupwithunstimulatedhumanPBMCs (yellow)andwideseparationofPMA/ionomycin-stimulatedhumanPBMCs (gray).
(B and C) A similar trend was seen for activated helper T cells (CD4+CD45RO, B) and activated cytotoxic T cells (CD8+CD45RO, C) isolated from the spleens of
hBLT mice.
(D) Human immune cells isolated from hBLTmice show an impaired immune profile compared with the human control samples. Human T cells were isolated from
hBLT blood at week 8 (p0), week 16 (p3), and week 20 (p4) (n = 5 mice per time point) after humanization, and the RNA expression profile was compared with
T cells isolated from healthy human blood samples. At p0, the immune profile of hBLT T cells is most similar to control T cells, despite some marked increases in
pro-inflammatory cytokine profiles at that time point. In contrast, other genes involved in T cell inhibition (FOXP3, TGFB1) are hardly expressed at baseline, but
their expression increases over time during the aging of the mice. Interestingly, at p3, the ESC-derived ECs and HUVECs were engrafted, but this did not result in
changes in the immune profile at p4.
(E) Human T cells isolated from hBLT mice develop T cell anergy and senescence upon aging. At p0, the T cell anergy gene profile of human T cells is similar to
human control T cells. However, upon aging of the hBLTmice, the anergic profile becomes increasingly present (left). A similar result was seen for the inhibitory
molecules (right). Also, the engraftment of allogeneic cells at p3 did not result in an alteration from an inhibitory to a pro-inflammatory immune profile.antigen stimulus. However, the strong correlation between graft
loss and the presence of CD45RO+ lymphocytes seems to
indicate that the graft-infiltrating lymphocytes were properly
stimulated to target the grafts earlier in the response but that
the immune response had subsided. Therefore, we analyzed
gene expression profiles in hBLT splenocytes associated withT cell anergy and exhaustion. T cell exhaustion is described in
cases of chronic infection and continuous exposure to foreign
antigens and is associated with the upregulation of genes such
as CTLA4, LAG3, and TIM3 (Wherry, 2011). Human activated
memory helper T cells (CD4+CD45RO+) and activated memory
cytotoxic T cells (CD8+CD45RO+) isolated from the spleenCell Reports 20, 1978–1990, August 22, 2017 1983
showed higher expression levels of these genes compared with
unstimulated and stimulated PBMCs from the healthy human
control (Figure S5C), providing initial signs for exhaustion of
the human lymphocytes. A full-scale immune response cannot
be mounted by these CD4+CD45RO+ and CD8+CD45RO+ lym-
phocytes, potentially explaining the inability of the hBLT model
to fully reject allogeneic hESC grafts.
To assess where in the development of the hBLT model the
failure in graft rejection occurs, we next analyzed the immune
cells of hBLT mice (n = 5) at different time points during the hu-
manization process. Blood samples from five hBLT mice were
drawn at week 8 (p0), 16 (p3), and 20 (p4) after humanization,
and human T cells were isolated for RNA sequencing (RNA-
seq). The immune profile was then compared with T cells from
a healthy control human blood sample (ctrl). The immune profile
of human immune cells within the hBLT model at week 8 post-
humanization reveals an immune profile similar to the human
control sample, but, by weeks 16 and 20, this immune profile
starts to diverge and shows significant upregulation of immune
profiles associated with T cell anergy and upregulation of
inhibitory molecules (Figures 4D and 4E).
Allogenized Mice Have a More Organized Lymphoid
Architecture Than Humanized Mice and Can Reject
Xenogeneic and Allogeneic iPSCs
Our data so far have demonstrated the superior engraftment of
human immune cells in the hBLT model, but the model appears
to have a limited ability to mount a robust full-scale allogeneic
immune response to human PSCs over time. To determine
whether this is ‘‘model-dependent,’’ we next created allogenized
mouse models by reconstituting NSG mice with allogeneic
C57BL/6 mouse bone marrow (aBM mice) as well as mouse
bone marrow, liver, and thymus (aBLT mice). Donor immune
cells, as well as fetal liver and thymus transplanted in the
abdomen, remained viable for up to one year in these models
(Figure S6A).
Engraftment of donor immune cells in allogenized NSG mice
was assessed by flow cytometry 12 weeks post-HSC transplan-
tation. Donor cells were identified based on the CD45 allelic
disparity between donor C57BL/6 (CD45.2) and recipient NSG
(CD45.1) mice. Both the aBM and the aBLT allogenized mouse
models had high levels of donor immune cell engraftment. The
percentages of total leukocytes, T cells, B cells, and NK cells
in peripheral blood were similar between the two models and
did not differ from wild-type C57BL/6 mice (Figure S6B).
We examined the lymphoid structures in aBLT mice and
compared these with the lymphoid structures in the hBLT
mice, wild-type C57BL/6 mice, and unmanipulated negative
control NSG mice (Figure 5A). H&E analysis of the spleens of
hBLT mice revealed marked hematopoiesis but minimal periar-
teriolar lymphocyte migration (Figures 5C and 5E, center). Inter-
estingly, this splenic architecture does mature over time with the
development of a marginal zone by week 24 after humanization
(Figure S7). In dLNs, human lymphocytes were found in minimal
quantities at week 12 compared with the wild-type mouse
(Figure 5F, left and center). In contrast, the spleen of the allogen-
ized mouse at week 12 after humanization had a very similar
architecture as the wild-type C57BL/6 mouse (Figures 5B and1984 Cell Reports 20, 1978–1990, August 22, 20175E), with periarteriolar lymphoid sheaths but without apparent
germinal center B cell areas. In addition, the lymphoid areas of
allogenized mouse spleens had irregular margins, consistent
with missing marginal zone-type cell development or paucity of
the perilymphoid macrophage-rich collections that are part of
the specialized open and closed circulation (Figures 5D and
5E, right). Analysis of the dLNs in the allogenizedmouse revealed
high levels of lymphocytes, indicating migration of the lympho-
cytes to peripheral lymphoid organs (Figure 5F, right).
Next, allograft responses in the aBM and aBLT models were
examined in vivo against allogeneic miPSCs. Allogenized mice
were injected with 1 3 105 labeled miPSCs i.m. or i.s., and
the survival of miPSC grafts was monitored longitudinally using
BLI. The allogenized mice showed robust rejection of miPSC
implanted i.m., similar to immunocompetent C57BL/6 mice,
although rejection was delayed by 7 days compared with
that observed in C57BL/6 mice (Figures 6A and 6C). In contrast,
the PSC survival kinetics in the spleens of allogenized mice
were indistinguishable from immunocompetent mice (Figures
6B and 6D), and no differences were observed between the
aBM and aBLT models with respect to their capacity to reject
allografts (Figure S6C). Allogenized mice also developed robust
immune responses that resulted in rapid rejection of hESCs,
although rejection of hESCs injected i.m. or i.s. was again
slightly delayed by 4–7 days compared with that of immuno-
competent mice (Figures 6E–6H). Overall, these findings
suggest that the allogeneic thymus offers an adequate microen-
vironment for appropriate mouse T cell development that leads
to a robust allograft response. Furthermore, these data suggest
that allograft responses can be modeled in reconstituted NSG
mice, although there was a delay in rejection of the PSCs at
some sites in the allogenized mice compared with wild-type
C57BL/6 mice.
Allogenized Mice Demonstrate Impaired Immune
Responses to Minor Histocompatibility-Mismatched
Stem Cell Grafts
To investigate the ability of allogenized mice to reject minor
histocompatibility-mismatched grafts, we next implanted
mESCs with an immunological mismatch at the minor histocom-
patibility antigen (mHA). The mESCs from the 129S1/SvlmJ
strain (H2KbDb) were injected i.m. or i.s. into allogenized mice
(donor cells from C57BL/6J mice, H2KbDb). In contrast to immu-
nocompetent mice (C57BL/6), allogenized mice were unable to
reject mHA-mismatched mESCs at either implantation site.
The rate of tumor growth in allogenized mice was slightly slower
than in non-engrafted NSG mice. Nevertheless, large teratomas
without signs of regression developed within 30 days in allogen-
ized and NSG mice (Figures 7A–7D).
To gain insights into the defective immune responses found in
the allogenizedmice in response tomHA-mismatched grafts, we
next examined cytokine production of splenocytes from mHA-
mismatched allogenized mice. Production of IFN-g by spleno-
cytes in response to short-term PMA and ionomycin stimulus
was found to be significantly diminished compared with immu-
nocompetent C57BL/6 mice (Figure 7E). Overall, the slower
growth of mHA grafts in our allogenized mice shows limited
effectiveness in rejecting mHA cells. However, the significant
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Figure 5. Allogenized Mice Have a More Organized Lymphoid Architecture that Is Similar to Wild-Type Mice
(A) Overview of splenic tissue in NSG mice with poorly developed splenic architecture (H&E, 23 magnification).
(B) Normal splenic architecture in a wild-type C57BL/6 mouse with a periarteriolar T cell area, B cell area (asterisk), and marginal zone (arrowheads) (H&E,
103 magnification).
(C) hBLT mice show a high degree of hematopoiesis in the spleen but little periarteriolar T cell migration and an overall disorganized splenic architecture (H&E,
103 magnification).
(D) Allogenized mice have an architecture more similar to the wild-type C57BL/6 mouse, with periarteriolar lymphoid sheets. However, apparent germinal center
B cell areas as well as marginal zones are missing, giving the periarteriolar margins an irregular shape (H&E, 103 magnification).
(E) Higher-magnification images (403) of sites of interest in (B)–(D).
(F) Overview of inguinal dLNs, showing high levels of lymphocyte infiltration in wild-type C57BL/6 (left) and allogenized mice (right) compared with the hBLT
mouse model (center) (H&E, 403 magnification).reduction of IFN-g levels in response to PMA and ionomycin
reveals an inability of the reconstituted immune system to
respond appropriately to mHA grafts.
DISCUSSION
Preclinical trials using humanized mice could prove to be crucial
in addressing the efficacy and safety of supportive therapies
necessary for the maintenance of PSC grafts. One report
addressed the immunogenicity of CTLA4-Ig- and PD-L1-overex-
pressing PSC grafts using the hBLTmodel (Rong et al., 2014). An
immune response to hESCs, marked by lymphocyte infiltration
and necrosis of teratomas, was observed. However, solely
relying on T cell infiltration is an insufficient measure of graft
rejection because infiltrates may, in fact, be suppressing the
immune response (de Almeida et al., 2014). This is supported
by our observation of T cell infiltration in our humanized mice
that did not result in graft rejection. We therefore utilized in vivo
BLI to track graft survival over time instead of relying solely on
histopathology. In addition, central necrosis of tumors formed
after injection of PSCs can also occur when proliferative growthis too high or toomany PSCs are injected, as has been described
in performing teratoma assays (Nelakanti et al., 2015).
We tested two humanized mouse models, hSRC and hBLT, to
assess human immune responses to human allogeneic undiffer-
entiated ESCs and ESC derivatives. Comparing these two
mouse models, our results suggest that a functional full-scale
immune response capable of rejecting human PSCs and their
derivatives does not develop in these mice. We demonstrated
this by first transplanting undifferentiated hESCs into hSRC
mice. Because of the limitations of the hSRC mouse to properly
educate human T cells in the murine thymus, we transplanted
these cells in the hBLT model. Even though these hBLT mice
were better reconstituted with human immune cells, the hBLT
model still presents with abnormal reconstitution of certain sub-
sets, such as CD8+ T cells as well as NK cells and other innate
immune cells (Rongvaux et al., 2014). Similar to the hSRCmodel,
the hBLTmodel was unable to reject miPSCs, allogeneic hESCs,
differentiated hESC-ECs, and somatic HUVECs. In some hBLT
mice, with higher numbers of intra-graft naive and regulatory
T cells, graft survival even improved compared with NSG mice.








Figure 6. Allogenized Mice Show Robust Rejection of Allogeneic miPSC Grafts and Xenogeneic Human IFN-g-Stimulated ESC Grafts
(A) Robust but somewhat delayed rejection of miPSC allografts injected i.m.
(B) miPSC allografts injected i.s. were rejected at a similar rate as in immunocompetent C57BL/6 mice.
(C and D) Quantification of the BLI data from (A) and (B), respectively, normalized to the maximum radiance on day 1.
(E and F) More rapid rejection of xenogeneic hESCs injected (E) i.m. and (F) i.s. but, again, delayed by 7 days compared with immunocompetent mice.
(G and H) Quantification of the BLI data from (E) and (F), respectively, normalized to the maximum radiance on day 1.
BLI data are represented as mean ± SEM from four independent experiments (n = 3).proven to be useful in the modeling of rejection of skin grafts and
human islet grafts (Xiao et al., 2014). In our model, there was a
strong correlation between activated immune cells and graft
loss, indicating that an effective immune response to the
hESC-EC grafts developed at some point. However, the limited
presence of immune cells in the dLNs and allografts suggests
reduced clonal expansion of effector T cells in these tissues.
This was confirmed by FACS analysis and H&E staining of the
dLNs, which showed limited presence of lymphocytes and mac-
rophages as well as disorganized lymphoid structures, respec-
tively. Both negatively influence adequate antigen presentation
and subsequent stimulation of T cells.
Single-cell PCR analysis of the small percentage of activated
(CD45RO+) lymphocytes found in the grafts, as well as spleno-
cytes isolated from hBLT mice, showed a similar immunological
phenotype to unstimulated PBMCs isolated from a healthy
human donor, which contrasted sharply with PMA and ionomy-
cin-stimulated healthy donor PBMCs. Even though the amount
of CD45RO+ T cells was small in the spleens and PSC grafts of1986 Cell Reports 20, 1978–1990, August 22, 2017humanized mice, CD45RO+- and CD44+-expressing CD8+ lym-
phocytes in the blood were increased to 20%, providing
evidence for a systemically activated immune system. Additional
RNA-seq data, derived from hBLT immune blood cells at
different time points during humanization, further show the
development of an anergic or exhausted T cell phenotype over
time after an initial activated immune profile. In vivo testing of
the different immune cells from the lymphoid organs was per-
formed after the transplant studies by re-exposing them to anti-
gens from the transplanted cells, unencountered antigens, or a
non-antigen-specific stimulus with PMA/ionomycin. However,
none of the conditions described above resulted in the upregula-
tion of pro-inflammatory cytokines and an overall inability to be
activated.
We hypothesized that the education of human immune cells
in the human fetal thymus failed to completely tolerize the
developing human T cells to murine antigens, leading to an acti-
vated systemic immune system and a subsequent increase in






Figure 7. Allogenized Mice Fail to Reject mHA-Mismatched ESC Murine Allografts and Have Reduced IFN-g Responses
(A and B) Allogenizedmicewere unable to reject mHA-mismatched 129S1/SvImJmESCs injected (A) i.m. (n = 5) or (B) i.s. (n = 5), and their BLI signal was similar to
unmanipulated NSG mice (n = 4), whereas immunocompetent mice (n = 4, n = 5) rapidly rejected these grafts at both implantation sites.
(C and D) Quantification of the BLI data from (A) and (B), respectively, normalized to the maximum radiance on day 1.
(E) Significantly reduced production of IFN-g from allogenized mouse splenocytes exposed to mHA-mismatched mESCs using a multiplex-Luminex platform.
Cytokine data are represented as mean ± SEM from one experiment (n = 3).wasting disease-like syndrome in hBLT mice has been
described previously (Covassin et al., 2013; Greenblatt et al.,
2012; Lockridge et al., 2013), but not in all laboratories (Onoe
et al., 2011), and is correlated with a decrease of naive human
CD45RA cells in the blood, as seen in our hBLT mice. The
hBLT mice in our study were screened for chimerism 12 weeks
after humanization, the transplant studies were initiated
20 weeks after humanization, and the mice were euthanized
4 weeks later. Having supporting RNA-seq and single-cell PCR
data that show exhaustion of the human lymphocytes, combined
with data showing impaired cytokine production during that
time, indicates that there is a limited time frame for modeling
human immune responses in these mice.
To test the feasibility of reconstituting an NSG mouse with a
functional immune system that is capable of rejecting allogeneic
PSC grafts, we next created an allogenized mouse model with
allogeneic murine fetal bone marrow, thymus, and liver. This
allogenized mouse model and the transplanted allogeneic he-
matopoietic and immune system remained viable for up to ayear. Functionally, our allogenized mouse was able to fully reject
the human grafts and allogeneic murine grafts. However, the
allogenized mouse was unable to reject the mHA-mismatched
mESCs, and these cells proliferated without signs of rejection.
Cytokine profile analysis of their spleens revealed significantly
lower levels of IFN-g, which has important immunostimulatory
effects and is critical for effective innate and adaptive immune re-
sponses. IFN-g is produced predominantly by NK and NK
T (NKT) cells as part of the innate immune response and by
CD4+ T helper (Th) type 1 and CD8+ cytotoxic T cells when anti-
gen-specific immunity develops. Under normal circumstances,
NK and NKT cells show markedly increased IFN-g secretion
within hours after stimulation (Schoenborn and Wilson, 2007),
which did not occur in our allogenized mice. The presence of a
more organized lymphoid structure in the allogenized mouse
compared with the humanized mouse, as well as these immune
cells’ ability to be activated by allogeneic cytokines (Manz,
2007), might provide an explanation for why the allogenized
mouse was able to reject allogeneic and human grafts. However,Cell Reports 20, 1978–1990, August 22, 2017 1987
the absence of a fully functional innate immune system, as indi-
cated by the lower levels of IFN-g, resulted in a delayed immune
response to human and allogeneic murine grafts and an inade-
quate response to mHA-mismatched grafts.
In summary, we have shown, with the allogenized mouse, that
reconstitution of an immunodeficient mouse with a functional
immune system is feasible and would allow for the modeling of
PSC alloimmunity. However, current humanized mouse models
suffer from inadequate reconstitution of the innate immune
system and the development of a wasting disease-like syndrome
that renders them inadequate for long-term PSC transplant
studies. To limit the development of this syndrome, future efforts
will focus on genetic modification of the SIRPA-CD47 pathway
(i.e., providing a ‘‘don’t eat me signal’’) (Lavender et al., 2013)
as well as the continuing development of NSG mice that trans-
genically express HLA molecules in their thymus (Babad et al.,
2015; Shultz et al., 2010), therefore allowing HLA-restricted
T cell selection for both human and murine antigens. Moreover,
NSG mice expressing important human cytokines for innate and
adaptive immune responses, such as macrophage colony-stim-
ulating factor (M-CSF), IL-3/granulocyte macrophage colony-
stimulating factor (GM-CSF), and TPO, already exist (Rongvaux
et al., 2014), and combination of one or more properties of these
mice could result in a more effective model with which to
conduct studies of the immunobiology of PSC therapeutics.
EXPERIMENTAL PROCEDURES
Humanized and Allogenized Mouse Development
All experiments were performed with approval of the Animal Care and Use
Committee at Stanford University and the Institutional Animal Care and Use
Committee (IACUC) committee at University of Massachusetts Medical
School. Humanized hSRC mice (12 weeks old) were developed by g-irradi-
ating, 100 centigray (cGy), NOD.Cg-Prkdcscid IL2rgtm1Wj1/Sz (NSG) mice
(3-4 weeks old) and transplanting them with lineage depleted HSCs (100,000
CD34+ HSC). Humanized hBLT mice (12 weeks old; male) were developed
by g-irradiating (200 cGy) NSG mice (6–8 weeks old), surgically implanting
HLA-A2neg human fetal liver and thymus under the kidney capsule, and inject-
ing autologousHSCs (100,000 CD34+ HSC). All mice were screened for human
cell chimerism levels 12 weeks post-engraftment. Allogenized mice were
generated at Stanford University using a similar methodology as that used
for generating hBLT mice (Supplemental Experimental Procedures). Control
female mice, FVB/NJ mice, and C57BL/6J mice were purchased from The
Jackson Laboratory at 6–8 weeks of age and aged to match our humanized
and allogenized mice.
In Vivo BLI
Survival of transplanted hESC-ECs was longitudinally monitored with BLI
using the Xenogen In Vivo Imaging System (Caliper Life Sciences). After i.p.
injection of the reporter probe D-luciferin (375 mg/kg body weight), the mice
were placed in the light-tight chamber and imaged with integration times of
5 s to 2 min, depending on emission intensity. Quantification of the BLI signal
was performed by using the maximum photons per square centimeter and is
presented as Log10 (photons s-1).
Flow Cytometric Analysis of Graft-Infiltrating Lymphocytes
Cells were isolated from s.c. and i.m. injected grafts and resuspended in FACS
buffer (phosphate-buffered saline [PBS] containing 2% fetal bovine serum
[FBS] and 2 mM EDTA), and the Fc receptor was blocked by anti-human Fc
receptor-blocking antibody (Miltenyi Biotec). Samples were then stained
with fluorophore-conjugated monoclonal antibodies against murine CD45
and the following human markers: CD45, CD3, CD4, CD8, CD25, FoxP3,
CD11b, and NK1.1 (1:100; BD Biosciences, eBioscience, BioLegend, and1988 Cell Reports 20, 1978–1990, August 22, 2017Thermo Fisher). Cells were fixed and permeabilized using BD Cytofix/Cyto-
perm fixation, and intracellular staining was performed. Cells were assayed
using an LSRII flow cytometer (BD Biosciences) and further analyzed with
FlowJo software (Tree Star, Ashland, OR, USA).
RNA-Seq
CD45+ and CD3+ cells were isolated by flow cytometry using a FACSAria II
special order research product (SORP) flow cytometer (BD Biosciences). Total
RNA was extracted and quantified using the miRNeasy Kit (QIAGEN) accord-
ing to the manufacturer’s protocol. Ten nanograms of total RNA was used to
generate index-tagged paired-end cDNA libraries. Briefly, mRNAs were
purified and then amplified to cDNA using the Ovation RNA-Seq System V2
(NuGEN). Libraries were prepared and indexed using the NEBNext Ultra
DNA Library Prep Kit for Illumina and NEBNext Multiplex Oligos. Sequencing
was performed with Illumina’s HiSeq4000 platform using paired-end reads
at an average length of 100 bp (2 3 100).
RNA-Seq Analysis
The sequenced reads were aligned to the human genome (hg19, downloaded
from University of California, Santa Cruz [UCSC]) by HISAT2 (https://ccb.jhu.
edu/software/hisat2/index.shtml; Pertea et al., 2016). We then used Feature-
Counts (http://bioinf.wehi.edu.au/featureCounts/; Liao et al., 2014) to quanti-
tate the transcriptome with genome annotation GENCODE 19 (hg19, version
19). DESeq2 (https://bioconductor.org/packages/release/bioc/html/DESeq2.
html; Loveet al., 2014) of Bioconductorwasapplied to the raw readsof the tran-
scriptome to normalize and generate the table of differentially expressed genes
(DEGs) (likelihood ratio test [LRT], p < 0.05). Hierarchical clustering was then
implemented on the DEGs. Function enrichment analyses of the DEG clusters
were then implemented by GeneAnswers from Bioconductor (https://www.
bioconductor.org/packages/release/bioc/html/GeneAnswers.html).
Single-Cell PCR Analysis
Gene expression of single cells was done using a 96.96 Dynamic Array chip
(M96, Fluidigm). Single cells were sorted into each well of a 96-well PCR plate.
After cell sorting and brief PCR plate centrifugation, the plate was placed in a
thermocycler for reverse transcription into cDNA, followed bypre-amplification
for 18 cycles. Finally, samples and assays were loaded in the M96 Fluidigm
plate using a NanoFlex integrated fluidic circuits (IFC) controller (Fluidigm), fol-
lowed by real-time PCR in the BioMark high-definition (HD) system (Fluidigm).
The results were analyzed using the Fluidigm real-time PCR analysis software.
Multiplex-Luminex Cytokine Assay
Production of various cytokines was measured in cell culture supernatant
using amultiplex-Luminex (LabMap200 system, Luminex) together with Pano-
mics antibodies at the Human Immune Monitoring Center at Stanford
University.
Statistical Methods
Statistical tests were performed using GraphPad Prism software. Bar graphs
represent the mean and SEM for each group. R package FactoMineR (http://
cran.r-project.org/web/packages/FactoMineR/index.html) was applied for
PCAandvisualizationofgeneexpression.Thestatisticalmethodused inFigure3
for thecorrelationanalysiswasaPearsoncorrelation test. InFigure7E, themean
levelsof IFN-gbetween twogroupswerecomparedusinganunpairedStudent’s
t test. Theengraftmentdata inFigureS3Bwereanalyzedbycomparing themean
percentage of cells between two groups using multiple t tests.
ACCESSION NUMBERS
The accession number for the raw and processed data from the next-genera-
tion RNA-seq experiments reported in this paper is NCBI GEO: GSE100791.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, and two tables and can be
foundwith this article online at http://dx.doi.org/10.1016/j.celrep.2017.08.003.
AUTHOR CONTRIBUTIONS
N.G.K., P.E.d.A., and J.P.S. conceived, performed, and interpreted the exper-
iments and wrote the manuscript. R.V.N. assisted with cell implantation and
BLI. R.J.S. and S.D. assisted with ESC differentiation. V.S.F. conducted the
gene expression analysis by Fluidigm. N.Y.S. performed biostatistical
analyses on the single-cell PCR and RNA-seq data. E.M. performed immuno-
fluorescence staining of tissue grafts. C.L. assisted with flow cytometry
sample processing and data acquirement. A.J.C. performed histology analysis
on tissue samples. M.A.B. and D.L.G. provided the humanized mice, experi-
mental advice, and manuscript writing. L.D.S. provided experimental advice
and manuscript writing. J.C.W. conceived study, provided experimental
advice, manuscript writing, and funding support.
ACKNOWLEDGMENTS
We would like to thank J. Durruthy-Durruthy for assistance with the single-cell
PCR, Xin Zhao for assistance with blood collection from mice, Mingtao Zhao
and Jared Churko for assistance with RNA-seq library preparation, and B.
Wu and J. Gold for editing the manuscript. This work was supported in part
by California Institute of Regenerative Medicine (CIRM) grants RT3-07798
and DR2A-05394; NIH grants R01 HL132875, R01 AI085575, and R01
HL133272 (to J.C.W.), P30 CA034196 (to L.D.S.), UC4 DK104218 (to D.L.G.,
L.D.S., and M.A.B.), and T32 OD01112 (to J.P.S.); and Helmsley Charitable
Trust Grant 2012PG-T1D018 (to D.L.G., L.D.S., and M.A.B.).
Received: July 9, 2015
Revised: April 23, 2017
Accepted: July 26, 2017
Published: August 22, 2017
REFERENCES
Babad, J., Mukherjee, G., Follenzi, A., Ali, R., Roep, B.O., Shultz, L.D., Santa-
maria, P., Yang, O.O., Goldstein, H., Greiner, D.L., and DiLorenzo, T.P. (2015).
Generation of b cell-specific human cytotoxic T cells by lentiviral transduction
and their survival in immunodeficient human leucocyte antigen-transgenic
mice. Clin. Exp. Immunol. 179, 398–413.
Barberi, T., Klivenyi, P., Calingasan, N.Y., Lee, H., Kawamata, H., Loonam, K.,
Perrier, A.L., Bruses, J., Rubio, M.E., Topf, N., et al. (2003). Neural subtype
specification of fertilization and nuclear transfer embryonic stem cells and
application in parkinsonian mice. Nat. Biotechnol. 21, 1200–1207.
Bosma, G.C., Custer, R.P., and Bosma,M.J. (1983). A severe combined immu-
nodeficiency mutation in the mouse. Nature 301, 527–530.
Brehm, M.A., Wiles, M.V., Greiner, D.L., and Shultz, L.D. (2014). Generation of
improved humanized mouse models for human infectious diseases.
J. Immunol. Methods 410, 3–17.
Covassin, L., Jangalwe, S., Jouvet, N., Laning, J., Burzenski, L., Shultz, L.D.,
and Brehm, M.A. (2013). Human immune system development and survival
of non-obese diabetic (NOD)-scid IL2rg(null) (NSG)mice engraftedwith human
thymus and autologous haematopoietic stem cells. Clin. Exp. Immunol. 174,
372–388.
de Almeida, P.E., Ransohoff, J.D., Nahid, A., and Wu, J.C. (2013). Immunoge-
nicity of pluripotent stem cells and their derivatives. Circ. Res. 112, 549–561.
de Almeida, P.E., Meyer, E.H., Kooreman, N.G., Diecke, S., Dey, D., Sanchez-
Freire, V.,Hu, S., Ebert, A.,Odegaard, J.,Mordwinkin,N.M., et al. (2014). Trans-
planted terminally differentiated inducedpluripotent stemcells are acceptedby
immune mechanisms similar to self-tolerance. Nat. Commun. 5, 3903.
Drukker, M., Katz, G., Urbach, A., Schuldiner, M., Markel, G., Itskovitz-Eldor,
J., Reubinoff, B., Mandelboim, O., and Benvenisty, N. (2002). Characterization
of the expression of MHC proteins in human embryonic stem cells. Proc. Natl.
Acad. Sci. USA 99, 9864–9869.
Greenblatt, M.B., Vrbanac, V., Tivey, T., Tsang, K., Tager, A.M., and Aliprantis,
A.O. (2012). Graft versus host disease in the bone marrow, liver and thymus
humanized mouse model. PLoS ONE 7, e44664.Greiner, D.L., Hesselton, R.A., and Shultz, L.D. (1998). SCID mouse models of
human stem cell engraftment. Stem Cells 16, 166–177.
Hesselton, R.M., Greiner, D.L., Mordes, J.P., Rajan, T.V., Sullivan, J.L., and
Shultz, L.D. (1995). High levels of human peripheral blood mononuclear cell
engraftment and enhanced susceptibility to human immunodeficiency virus
type 1 infection in NOD/LtSz-scid/scid mice. J. Infect. Dis. 172, 974–982.
Homma,K.,Okamoto,S.,Mandai,M.,Gotoh,N.,Rajasimha,H.K.,Chang,Y.S.,
Chen, S., Li,W.,Cogliati, T., Swaroop,A., andTakahashi,M. (2013). Developing
rods transplanted into the degenerating retina of Crx-knockout mice exhibit
neural activity similar to native photoreceptors. Stem Cells 31, 1149–1159.
Ishikawa, F., Yasukawa, M., Lyons, B., Yoshida, S., Miyamoto, T., Yoshimoto,
G., Watanabe, T., Akashi, K., Shultz, L.D., and Harada, M. (2005). Develop-
ment of functional human blood and immune systems in NOD/SCID/IL2 recep-
tor gamma chain(null) mice. Blood 106, 1565–1573.
Ito, M., Hiramatsu, H., Kobayashi, K., Suzue, K., Kawahata, M., Hioki, K.,
Ueyama, Y., Koyanagi, Y., Sugamura, K., Tsuji, K., et al. (2002). NOD/SCID/
gamma(c)(null) mouse: an excellent recipient mouse model for engraftment
of human cells. Blood 100, 3175–3182.
Lan, P., Tonomura, N., Shimizu, A., Wang, S., and Yang, Y.G. (2006). Recon-
stitution of a functional human immune system in immunodeficient mice
through combined human fetal thymus/liver and CD34+ cell transplantation.
Blood 108, 487–492.
Lavender, K.J., Pang, W.W., Messer, R.J., Duley, A.K., Race, B., Phillips, K.,
Scott, D., Peterson, K.E., Chan, C.K., Dittmer, U., et al. (2013). BLT-humanized
C57BL/6 Rag2-/-gc-/-CD47-/- mice are resistant to GVHD and develop B- and
T-cell immunity to HIV infection. Blood 122, 4013–4020.
Liao, Y., Smyth, G.K., and Shi, W. (2014). featureCounts: an efficient general
purpose program for assigning sequence reads to genomic features. Bioinfor-
matics 30, 923–930.
Lockridge, J.L., Zhou, Y., Becker, Y.A., Ma, S., Kenney, S.C., Hematti, P., Cap-
itini, C.M., Burlingham, W.J., Gendron-Fitzpatrick, A., and Gumperz, J.E.
(2013). Mice engrafted with human fetal thymic tissue and hematopoietic
stem cells develop pathology resembling chronic graft-versus-host disease.
Biol. Blood Marrow Transplant. 19, 1310–1322.
Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold
change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550.
Lui, K.O., Howie, D., Ng, S.W., Liu, S., Chien, K.R., and Waldmann, H. (2014).
Tolerance induction to human stem cell transplants with extension to their
differentiated progeny. Nat. Commun. 5, 5629.
Mandai, M., Watanabe, A., Kurimoto, M., Hirami, Y., Morinaga, C., Daimon, T.,
Fujihara, M., Akimuru, H., Sakai, N., Shibata, Y., Terada, M., et al. (2017).
Autologous induced stem-cell-derived retinal cells for macular degeneration.
NEJM 376, 1038–1046.
Manz, M.G. (2007). Human-hemato-lymphoid-systemmice: opportunities and
challenges. Immunity 26, 537–541.
Melkus, M.W., Estes, J.D., Padgett-Thomas, A., Gatlin, J., Denton, P.W., Oth-
ieno, F.A., Wege, A.K., Haase, A.T., and Garcia, J.V. (2006). Humanized mice
mount specific adaptive and innate immune responses to EBV and TSST-1.
Nat. Med. 12, 1316–1322.
Nelakanti, R.V., Kooreman, N.G., and Wu, J.C. (2015). Teratoma formation: a
tool for monitoring pluripotency in stem cell research. Curr. Protoc. Stem Cell
Biol. 32, 4A.8.1–4A.8.17.
Nguyen, P.K., Neofytou, R.J., and Wu, J.C. (2016). Potential strategies to
address the major clinical barriers facing stem cell regenerative therapy for
cardiovascular disease: a review. JAMA Cardiol 1, 953–962.
Onoe, T., Kalscheuer, H., Danzl, N., Chittenden, M., Zhao, G., Yang, Y.G., and
Sykes, M. (2011). Human natural regulatory T cell development, suppressive
function, and postthymic maturation in a humanized mouse model.
J. Immunol. 187, 3895–3903.
Pagliuca, F.W., Millman, J.R., G€urtler, M., Segel, M., Van Dervort, A., Ryu, J.H.,
Peterson, Q.P., Greiner, D., and Melton, D.A. (2014). Generation of functional
human pancreatic b cells in vitro. Cell 159, 428–439.Cell Reports 20, 1978–1990, August 22, 2017 1989
Pertea, M., Kim, D., Pertea, G.M., Leek, J.T., and Salzberg, S.L. (2016). Tran-
script-level expression analysis of RNA-seq experiments with HISAT, StringTie
and Ballgown. Nat. Protoc. 11, 1650–1667.
Rong, Z., Wang,M., Hu, Z., Stradner, M., Zhu, S., Kong, H., Yi, H., Goldrath, A.,
Yang, Y.G., Xu, Y., and Fu, X. (2014). An effective approach to prevent immune
rejection of human ESC-derived allografts. Cell Stem Cell 14, 121–130.
Rongvaux, A., Willinger, T., Martinek, J., Strowig, T., Gearty, S.V., Teichmann,
L.L., Saito, Y., Marches, F., Halene, S., Palucka, A.K., et al. (2014). Develop-
ment and function of human innate immune cells in a humanizedmousemodel.
Nat. Biotechnol. 32, 364–372.
Schoenborn, J.R., and Wilson, C.B. (2007). Regulation of interferon-gamma
during innate and adaptive immune responses. Adv. Immunol. 96, 41–101.
Schwartz, S.D., Hubschman, J.P., Heilwell, G., Franco-Cardenas, V., Pan,
C.K., Ostrick, R.M., Mickunas, E., Gay, R., Klimanskaya, I., and Lanza, R.
(2012). Embryonic stem cell trials for macular degeneration: a preliminary
report. Lancet 379, 713–720.
Shultz, L.D., Schweitzer, P.A., Christianson, S.W., Gott, B., Schweitzer, I.B.,
Tennent, B., McKenna, S., Mobraaten, L., Rajan, T.V., Greiner, D.L., et al.
(1995). Multiple defects in innate and adaptive immunologic function in
NOD/LtSz-scid mice. J. Immunol. 154, 180–191.
Shultz, L.D., Lyons, B.L., Burzenski, L.M., Gott, B., Chen, X., Chaleff, S.,
Kotb, M., Gillies, S.D., King, M., Mangada, J., et al. (2005). Human lymphoid
and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice en-
grafted with mobilized human hemopoietic stem cells. J. Immunol. 174,
6477–6489.
Shultz, L.D., Saito, Y., Najima, Y., Tanaka, S., Ochi, T., Tomizawa, M., Doi, T.,
Sone, A., Suzuki, N., Fujiwara, H., et al. (2010). Generation of functional human
T-cell subsets with HLA-restricted immune responses in HLA class I express-1990 Cell Reports 20, 1978–1990, August 22, 2017ing NOD/SCID/IL2r gamma(null) humanized mice. Proc. Natl. Acad. Sci. USA
107, 13022–13027.
Soto-Gutiérrez, A., Kobayashi, N., Rivas-Carrillo, J.D., Navarro-Alvarez, N.,
Zhao, D., Okitsu, T., Noguchi, H., Basma, H., Tabata, Y., Chen, Y., et al.
(2006). Reversal of mouse hepatic failure using an implanted liver-assist device
containing ES cell-derived hepatocytes. Nat. Biotechnol. 24, 1412–1419.
Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells
from mouse embryonic and adult fibroblast cultures by defined factors. Cell
126, 663–676.
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K.,
and Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human
fibroblasts by defined factors. Cell 131, 861–872.
Takenaka, K., Prasolava, T.K., Wang, J.C., Mortin-Toth, S.M., Khalouei, S.,
Gan, O.I., Dick, J.E., and Danska, J.S. (2007). Polymorphism in Sirpa modu-
lates engraftment of human hematopoietic stem cells. Nat. Immunol. 8,
1313–1323.
Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., Waknitz, M.A., Swiergiel, J.J.,
Marshall, V.S., and Jones, J.M. (1998). Embryonic stem cell lines derived from
human blastocysts. Science 282, 1145–1147.
Traggiai, E., Chicha, L., Mazzucchelli, L., Bronz, L., Piffaretti, J.C., Lanzavec-
chia, A., and Manz, M.G. (2004). Development of a human adaptive immune
system in cord blood cell-transplanted mice. Science 304, 104–107.
Wherry, E.J. (2011). T cell exhaustion. Nat. Immunol. 12, 492–499.
Xiao, F., Ma, L., Zhao, M., Huang, G., Mirenda, V., Dorling, A., Lechler, R., and
Lombardi, G. (2014). Ex vivo expanded human regulatory T cells delay
islet allograft rejection via inhibiting islet-derived monocyte chemoattractant
protein-1 production in CD34+ stem cells-reconstituted NOD-scid IL2rgnull
mice. PLoS ONE 9, e90387.
